The role of Clu in a variety of metabolic diseases (such as non-alcoholic fatty liver disease (Seo et al., 2025; Park et al., 2018; Park et al., 2020), diabetes (Seo et al., 2020; Seo et al., 2018), obesity (Hoofnagle et al., 2010), etc.)has been supported by many research results. This evidence concerns the gene CLU and obesity due to melanocortin 4 receptor deficiency.